Plus therapeutics showcases leptomeningeal metastases programs at the 2024 sno annual meeting in houston, texas

Company will present results from the respect-lm phase 1 clinical trial of rhenium ( 186 re) obisbemeda for leptomeningeal metastases (lm) and discuss its plan for continued clinical development company will present results from the foresee trial of circulating tumors cells for improved diagnosis and disease monitoring of lm company to host an educational symposium featuring clinical experts discussing lm and plus' recent announcements for its lm therapeutic and diagnostic programs austin, texas, oct. 29, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, will have multiple opportunities to present data at the 2024 society for neuro-oncology (sno) annual meeting november 21-24, 2024 in houston, texas. data presentations and symposium include: presentations: title rhenium (186re) obisbemeda (rhenium nanoliposome,186rnl) for the treatment of leptomeningeal metastases (lm): summary of the phase 1 dose escalation study and phase 2 administered dose selection (ctni-63)     presenter andrew brenner, m.d.
PSTV Ratings Summary
PSTV Quant Ranking